PubMed

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D.

Diabetes Care. 2001 Nov;24(11):1951-6.PMID: 11679463 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D.

J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M681-5.PMID: 11682575 [PubMed - indexed for MEDLINE]Related articles

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

Ryan AS, Egan JM, Habener JF, Elahi D.

J Clin Endocrinol Metab. 1998 Jul;83(7):2399-404.PMID: 9661618 [PubMed - indexed for MEDLINE]Related articlesFree article

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

Egan JM, Meneilly GS, Habener JF, Elahi D.

J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.PMID: 12161508 [PubMed - indexed for MEDLINE]Related articlesFree article

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.

Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.

Regul Pept. 1994 Apr 14;51(1):63-74.PMID: 8036284 [PubMed - indexed for MEDLINE]Related articles

Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes.

Forbes A, Elliott T, Tildesley H, Finegood D, Meneilly GS.

Diabetes. 1998 Dec;47(12):1915-9.PMID: 9836524 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D.

Diabetes Care. 2003 Mar;26(3):837-42.PMID: 12610046 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.

Diabetologia. 1993 Aug;36(8):741-4.PMID: 8405741 [PubMed - indexed for MEDLINE]Related articles

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.

Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA.

Diabetes. 2001 Mar;50(3):565-72.PMID: 11246876 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.

Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM.

Diabet Med. 2000 Oct;17(10):713-9.PMID: 11110504 [PubMed - indexed for MEDLINE]Related articles

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 does not not acutely affect insulin sensitivity in healthy man.

Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O.

Diabetologia. 1996 Oct;39(10):1227-32.PMID: 8897012 [PubMed - indexed for MEDLINE]Related articles

Pulsatile insulin secretion in elderly patients with diabetes.

Meneilly GS, Veldhuis JD, Elahi D.

Diabetes Res Clin Pract. 2006 Aug;73(2):218-20. Epub 2006 Apr 18.PMID: 16621106 [PubMed - indexed for MEDLINE]Related articles

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Zander M, Christiansen A, Madsbad S, Holst JJ.

Diabetes Care. 2004 Aug;27(8):1910-4.PMID: 15277416 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA.

Diabetes. 2000 Apr;49(4):611-7.PMID: 10871199 [PubMed - indexed for MEDLINE]Related articlesFree article